Clinical trials: Diabetic Macular Oedema
Diabetic Retinopathy, Macular Edema
Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.
- Trial name
- IBERA-DME (NCT01487629)
- Testing
- Bevacizumab, Ranibizumab
- Where
- Brazil
- Volunteers
- 53 people
- Sponsor
- University of Sao Paulo
Diabetic Macular Edema
Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A
The goal of this clinical trial is to to evaluate the changes in retinal microvasculature secondary to intra-ocular pressure changes post intra-vitreal injection in patients with diabetic macular oedema highlighting the effect of…
- Trial name
- NCT05861466
- Testing
- intra-vitreal injection of Ranibizumab, anterior chamber paracentesis
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams University
Diabetic Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration
Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates
The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care.
- Conditions
- Diabetic Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration, Intravitreal Injection
- Trial name
- ADHERE (NCT07567898)
- Testing
- multidisciplinary protocolized intervention (MPI), Routine medical care & monitoring
- Volunteers
- 200 people
- Sponsor
- Singapore Eye Research Institute
Diabetic Macular Edema
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy
The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of…
- Trial name
- NCT01319487
- Testing
- 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Fovea Pharmaceuticals SA
Diabetic Macular Edema
Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema
The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.
- Trial name
- Tribeva-DME (NCT00874744)
- Testing
- Bevacizumab, Triamcinolone acetonide
- Volunteers
- 13 people
- Sponsor
- Universidade Federal de Goias
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
- Trial name
- BLUE SKY (NCT04543331)
- Testing
- brolucizumab
- Where
- 41 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Oedema
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.
- Trial name
- ARA290DMO (NCT06626971)
- Testing
- ARA290
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Belfast Health and Social Care Trust
Diabetic Macular Edema, DME
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
- Trial name
- NCT07199777
- Testing
- SNP318
- Volunteers
- 60 people
- Sponsor
- SciNeuro
Diabetic Macular Edema
Ranibizumab and Bevacizumab for Diabetic Macular Edema
Background: Diabetic macular edema is a common eye complication of diabetes. It causes the blood vessels in the retina at the back of the eye to leak, causing swelling.
- Trial name
- NCT01610557
- Testing
- Ranibizumab, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Macular Edema
Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM
This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Maculopathy
- Trial name
- DR-NeoRetina (NCT04699864)
- Testing
- Screening of DR and DME with artificial intelligence using NeoRetina, Routine ophthalmological evaluation of DR and DME, Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diabetic Macular Edema
Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema
Macular edema is the main cause of low vision in diabetics. They continue looking for new treatment alternatives. The nutritional supplement Alzer, is a powerful antioxidant that together with Diamel, a supplement that has shown…
- Trial name
- NCT03533478
- Testing
- Oral treatment Alzer y Diamel
- Where
- Cuba
- Volunteers
- 64 people
- Sponsor
- Catalysis SL
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Currently, two similar medications are available for injection into the eye to treat a variety of eye diseases. These medications are called ranibizumab (Lucentis) and bevacizumab (Avastin).
- Trial name
- NCT01661946
- Testing
- Bevacizumab, Ranibizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Queen's University
Diabetic Macular Edema
Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
Retrospective multi-center observational study on functional and morphological outcome of initial therapy for DME according to ESASO Morphologic Classification.
- Trial name
- NCT05080803
- Testing
- intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
- Where
- Switzerland
- Volunteers
- 608 people
- Sponsor
- European School of Advanced Studies in Ophthalmology
Diabetic Macular Edema
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema.
- Trial name
- DIME (NCT02471651)
- Testing
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4…
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT06664502
- Testing
- EYE201
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- EyeBiotech Ltd.